Summary
Background Artemether-lumefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine plus amodiaquine is used for seasonal malaria chemoprevention. We determined the efficacy of artemether-lumefantrine with and without primaquine and sulfadoxine-pyrimethamine plus amodiaquine with and without tafenoquine for reducing gametocyte carriage and transmission to mosquitoes.
Methods In this phase 2, single-blind, randomised clinical trial conducted, asymptomatic individuals aged 10-50 years with P. falciparum gametocytaemia were randomised (1:1:1:1) to receive either artemether-lumefantrine, artemether-lumefantrine with a single dose of 0·25 mg/kg primaquine, sulfadoxine-pyrimethamine plus amodiaquine or sulfadoxine-pyrimethamine plus amodiaquine with a single dose of 1·66 mg/kg tafenoquine. All trial staff other than the pharmacist were blinded. The primary outcome was the median within person percent change in mosquito infection rate in infectious individuals from baseline to day 2 (artemether-lumefantrine groups) or 7 (sulfadoxine-pyrimethamine plus amodiaquine groups) post treatment, assessed by direct membrane feeding assay. This study is registered withClinicalTrials.gov, NCT05081089.
Findings Between 13 Oct and 16 Dec 2021, 1290 individuals were screened and 80 were enrolled and randomly assigned to one of the four treatment groups (20 per group). In individuals who were infectious before treatment, the median percentage reduction in mosquito infection rate 2 days after treatment was 100% (IQR 97·2-100; n=19, p=0·026) with artemether-lumefantrine and 100% (100-100; n=19, p=0·0001) with artemether-lumefantrine with primaquine. Only two individuals infected mosquitoes on day 2 after artemether-lumefantrine and none at day 5. In contrast, the median percentage reduction in mosquito infection rate 7 days after treatment was 63·60% (IQR 0·62 to 100, n=20, p=0·009) with sulfadoxine-pyrimethamine plus amodiaquine and 100% (100-100; n=19, p<0·0001) with sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine.
Interpretation These data support the effectiveness of artemether-lumefantrine alone for preventing nearly all mosquito infections. In contrast, there was considerable post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine where the addition of a transmission-blocking drug may be beneficial in maximizing its community impact.
Funding Bill & Melinda Gates Foundation
Brief summary Sulfadoxine-pyrimethamine plus amodiaquine is commonly used for seasonal malaria chemoprevention. Artemether-lumefantrine is the most widely used treatment regimen for uncomplicated Plasmodium falciparum malaria, but studies to date have shown inconsistent activity of artemether-lumefantrine against P. falciparum gametocytes. This study shows considerable post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine but near complete prevention of mosquito infection after artemether-lumefantrine, even without primaquine. The addition of 8-aminoquinolines reduced transmission with both combinations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05081089
Funding Statement
This work was supported by the Bill and Melinda Gates Foundation (#INV-002098). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. TB and KJL are further supported by supported by the European Research Council (ERC-CoG 864180; QUANTUM). WS is supported by a Wellcome Trust fellowship (218676/Z/19/Z/WT).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry of the University of Science, Techniques, and Technologies of Bamako (Bamako, Mali) (No 2021/189/CE/USTTB), and the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (London, United Kingdom) (LSHTM Ethics Ref: 26257).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
